LOS ANGELES – May 25, 2022 – Stand Up To Cancer® (SU2C) today announced two new teams, the SU2C Lung Cancer Health Equity Research Team with support from Bristol Myers Squibb and “SU2C Catalyst® with support from Mirati Therapeutics.” Both teams build on important work being done by unique SU2C research programs focused on improving cancer health equity and bringing new and innovative therapies to patients faster.
“SU2C is committed to supporting the cutting-edge research efforts of talented investigators. We are excited to announce these two new teams as they investigate ways to improve cancer outcomes in unique ways,” said Russell Chew, president and CEO of Stand Up To Cancer. “As we continue to build upon our research portfolio, funding teams that are focused on health equity and improving therapies in a clinical setting is critical to saving more lives.”
The recently funded teams are:
To learn more about SU2C’s Health Equity Initiative, which aims to increase diversity in cancer clinical trials, initiate advocacy group collaborations and awareness campaigns, and fund research to improve cancer outcomes and screening rates in medically underserved communities, visit StandUpToCancer.org/HealthEquity.
To learn more about the SU2C Catalyst program, which encourages collaborative research between academics and companies to shorten the time it takes to get new treatments to patients, visit StandUpToCancer.org/Catalyst.
# # #
Stand Up To Cancer
About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of January 2022, more than 2,000 scientists representing more than 210 institutions are involved in SU2C-funded research projects.
Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, PhD, SU2C conducts rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.
Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Russell Chew serves as SU2C’s president and CEO.